PARSIPPANY, N.J.--(EON: Enhanced Online News)--Castle Creek Pharmaceuticals, LLC (CCP), a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, today announced completion of an exclusive license agreement for all U.S. rights to Arlevert® from Hennig Arzneimittel GmbH & Co. KG. Arlevert is a fixed-dose oral combination of cinnarizine and dimenhydrinate. Arlevert is approved in multiple European Union countries, where it is indicated for the treatment of patients with vertigo of various origins.
“We are very pleased to license Arlevert for the U.S., as vertigo is a complex problem, and combining two molecules with different modes of action could be important for addressing both the peripheral and central effects of vertigo”
“We are very pleased to license Arlevert for the U.S., as vertigo is a complex problem, and combining two molecules with different modes of action could be important for addressing both the peripheral and central effects of vertigo,” said Dr. Greg Licholai, President and Chief Scientific Officer at Castle Creek Pharmaceuticals. “Our goal is to expedite the development of Arlevert in the U.S. by building on the European patient experience of over 11 million prescribed doses and its track record of effectiveness, safety and tolerability. Arlevert will be an important addition to our pipeline, as it addresses a significant need for patients who suffer from the debilitating effects of vertigo.”
Previous well-controlled clinical studies have demonstrated that Arlevert has a significant efficacy profile, as measured by validated mean vertigo scores compared with placebo7,9, betahistine1,2,5,6,7,11 and the component mono-therapies3,4,9,10. Arlevert has also been well-tolerated with minimum sedation2,10.
“I am very happy that the possibility of a treatment modality available to the rest of the world is now being developed for patients in the United States,” said Dr. Sujana Chandrasekhar, MD, FACS, FAAO-HNS, past president of American Academy of Otolaryngology-Head and Neck Surgery, neuro-otologist and clinical professor at Hofstra-Northwell School of Medicine, and clinical associate professor at Icahn School of Medicine at Mount Sinai. “Our patients can be utterly debilitated due to vertigo and they could benefit from a medication that allows them to function better.”
Vertigo is a sensation caused by an imbalance in the signals from the body’s sensory balance organs, including the eyes and inner ears, or by the way such signals are interpreted by the brain. It is commonly perceived as instability, a feeling of rotation or the sensation of dizziness, and it is often associated with lack of balance, nausea and vomiting. Vertigo is caused by a wide number of underlying conditions, including benign paroxysmal positional vertigo, vestibular neuropathy, vertebrobasilar insufficiency, vestibular migraine and Menière’s disease. Vertigo is a common condition, and in recent studies, vertigo and dizziness together were found to affect 5-10 percent of the entire U.S. population and as much as 40 percent of the U.S. population over the age of 40 years.
Arlevert is a fixed-dose oral combination tablet containing 20 mg cinnarizine and 40 mg dimenhydrinate, to be taken three times daily. It is approved in multiple European Union countries for the treatment of vertigo of various origins8. When these two substances are used together, they are more effective than either of its component drugs alone. The active ingredients work together both peripherally and centrally to reduce the symptoms of vertigo. Cinnarizine is a calcium channel antagonist which peripherally affects the vestibular hair cells of the inner ear and dimenhydrinate is an antihistamine which centrally affects the vestibular nuclei of the brainstem. Dimenhydrinate also reduces nausea, which is a symptom of acute vertigo.
About Castle Creek Pharmaceuticals
Castle Creek Pharmaceuticals (CCP) is a high-growth biopharmaceutical company that has rapidly assembled a robust and diversified late-stage pipeline of products backed by strong science and focused on meeting patient needs in the treatment of rare and debilitating dermatologic and head and neck conditions.
About Hennig Arzneimittel
HENNIG ARZNEIMITTEL is an independent, family-run, mid-sized German pharmaceutical company with more than 118 years of experience in the manufacturing and marketing of pharmaceutical products. Over the past 35 years, the company has specialized in the treatment of vertigo and vestibular disorder. In this indication, HENNIG ARZNEIMITTEL is German market leader with Arlevert, its original drug for the treatment of patients with vertigo of various origins. By hosting the biannual HENNIG-Vertigo-Symposium, Europe’s largest event in this therapeutical area, and tendering the HENNIG-Vertigo-Award, HENNIG ARZNEIMITTEL fosters research and scientific exchange among investigators in this field of study. By supporting continued education for practitioners, ENT-physicians and neurologists, the company promotes better vertigo diagnosis and therapy. With its more than 300 highly qualified employees, state-of-the-art technologies and its own on-site production facilities, HENNIG ARZNEIMITTEL stands for the highest quality.
- Cirek Z, Schwarz M, Baumann W, Novotny M., Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo : A Double-Blind, Randomised Clinical Study. Clin Drug Investig. 2005;25(6):377-89.
- Hahn A, Sejna I, Stefflova B, Schwarz M, Baumann W. A Fixed Combination of Cinnarizine/Dimenhydrinate for the Treatment of Patients with Acute Vertigo Due to Vestibular Disorders Clin Drug Invest 2008; 28 (2): 89-99
- Hahn A, Novotny M, et. al. Comparison of Cinnarizine/Dimenhydrinate Fixed Combination with the Respective Monotherapies for Vertigo of Various Origins. Clin Drug Investig 2011; 31 (6): 371-383
- Keßler L, Bognar-Steinberg I, Baumann W, Skurczynski W. Treatment of vestibular vertigo: Comparison of a fixed combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg with the 2.5-fold higher dosed active drugs in monotherapy Archives of Sensology and Neurootology in Science and Practice-ASN; Volume 7, 2012
- Novotný M, Kostrica R., Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study. Int Tinnitus J. 2002;8(2):115-23.
- Novotny M, Bognar-Steinberg I, Baumann, W. Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Menière’s disease. Post hoc Non-inferiority Analysis of a Prospective, Randomized, Double-blind Study Archives of Sensology and Neurootology in Science and Practice-ASN Volume 6 – 2011 http://neurootology.org ISSN 1612 – 33521
- Otto V, Fischer B, Schwarz M, Baumann W, Preibisch-Effenberger R. Treatment of Vertebrobasilar Insufficiency-Associated Vertigo with a Fixed Combination of Cinnarizine and Dimenhydrinate International Tinnitus Journal, Vol. 14, No. 1, 57-67 (2008)
- Public Assessment Report, UK/H/984/001/MR, www.mhra.gov.uk. (http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con014026.pdf)
- Pytel J, Nagy G, Tóth A, Spellenberg S, Schwarz M, Répassy G. Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study. Clinical Therapeutics 2007; 29: 84-98.
- Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz HJ (2004): Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther. 26(6):866-77.
- Scholtz AW, Steindl R, Burchardi N, Bognar-Steinberg I, Baumann W (2012): Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study. Clin Drug Investig. 1;32(6):387-99.
For more information, visit: www.castlecreekpharma.com.